Thursday, February 2, 2017

VisCardia Finds $12.5M For Heart Failure Treatment

Portland-based VisCardia, a developer of implantable, heart failure treatment devices, has raised $12.5M in a Series B funding, the company said on Wednesday. The funding came from Kinetic Capital Partners. VisCardia said that, simultaneously with the funding, it has acquired the assets and technology rights from Inovise Medical. Michael Mirro has been named as Director of Medical Affairs along with the acquisition.